Figure 3 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

Kaplan–Meier survival analysis. fHRD status significantly predicts longer PFS and OS in chemo-naïve (A and C) and IDS (B and D) cohorts (Log-rank, Mantel–Cox test). Patients treated with PARPi in the first-line setting or with unknown PARPi treatment status were excluded from the PFS analysis (A and B). In addition to first-line and unknown PARPi treatment statuses, patients treated with PARPi at recurrence were excluded from OS analyses (C and D).